Company Profile: Kanova Biopharma
Overview
Kanova Biopharma (also operating under corporate entities such as Zhejiang Kanova Biopharmaceutical Co., Ltd. and Beijing Kanova Biopharmaceutical Co., Ltd., often referred to domestically as XinKangHe / 新康和) is a clinical-stage Chinese biotechnology enterprise founded in November 2015. Headquartered in China with main operations across Beijing and Zhejiang, the company was established by a world-renowned immunologist to focus on cutting-edge research and drug discovery in immunology and oncology.
Kanova operates as an innovation-driven biopharmaceutical developer aiming to discover and commercialize novel therapeutic antibodies, including first-in-class monoclonal and bispecific antibodies, for the treatment of autoimmune diseases, inflammatory disorders, and immuno-oncology indications.
Continue…
Strategic Focus and Core Mission
Kanova positions itself at the intersection of basic immunological discovery and translational medicine. The company focuses on addressing unmet global medical needs by discovering novel biological targets or engineering innovative combination therapies.
Key operational focus areas include:
* Autoimmune and Type 2 Inflammatory Diseases: Developing biologic drugs targeting inflammatory cytokines and immune checkpoints that drive conditions such as plaque psoriasis, ankylosing spondylitis, atopic dermatitis, and asthma.
* Immuno-Oncology: Researching therapeutic antibodies targeting tumor microenvironments and novel checkpoint pathways to improve response rates in cancer immunotherapy.
* Precision Innovation and IP Ownership: Generating proprietary intellectual property (IP) and leading first-in-class or best-in-class antibody drug candidate development from target validation through clinical evaluation.
Products and Pipeline Candidates
As a clinical-stage biotechnology company, Kanova does not sell off-the-shelf commercial pharmaceuticals directly to consumers. Instead, its product portfolio consists of therapeutic biological drug candidates undergoing clinical and preclinical development, alongside strategic licensing partnerships with pharmaceutical manufacturers.
1. XKH001 (Anti-IL-25 Monoclonal Antibody)
- Mechanism of Action: Recombinant humanized IgG1 monoclonal antibody targeting Interleukin-25 (IL-25), a key upstream cytokine involved in Type 2 immune responses.
- Indications: Moderate-to-severe atopic dermatitis, asthma, and other Type 2 inflammatory conditions.
- Development Status: Advanced into Phase II clinical trials following First-in-Human (FIH) safety, pharmacokinetics (PK), and pharmacodynamics (PD) evaluations in both China and under US FDA IND clearance.
2. Recombinant Human IL-17A/F Bispecific / Dual-Targeting Antibody (XKH004 / LZM012)
- Mechanism of Action: Dual-targeting therapeutic antibody engineered to neutralize both IL-17A and IL-17F homodimers and heterodimers, providing broader inhibition of the IL-17 pathway compared to selective IL-17A inhibitors.
- Indications: Plaque psoriasis, ankylosing spondylitis, and related autoimmune inflammatory musculoskeletal conditions.
- Strategic Out-Licensing & Status: Out-licensed in 2017 to Livzon MabPharm Inc. (Livzon Pharmaceutical Group) for clinical commercialization. Has successfully completed Phase III pivotal clinical trials meeting primary efficacy endpoints for autoimmune indications.
3. XKH-007 (Anti-CD276 / B7-H3 Antibody)
- Mechanism of Action: Monoclonal antibody targeting CD276 (B7-H3), an immune checkpoint molecule overexpressed on various solid tumor cells and tumor-infiltrating vascular endothelial cells.
- Indications: Oncology and solid neoplasms.
- Development Status: Preclinical discovery and early translational development.
R&D Capability and Services Model
Kanova operates an integrated biopharmaceutical research and development infrastructure supported by proprietary technology platforms:
- Antibody Engineering and Discovery Platform: Proprietary capabilities for target identification, antibody humanization, structural optimization, and bispecific construct design.
- Translational Medicine & Clinical Development: In-house capabilities for conducting regulatory IND filings in China (NMPA) and the United States (US FDA), managing Phase I to Phase III clinical trials, and performing bioanalytical evaluations (PK/PD and immunogenicity assays).
- Strategic Licensing and Partnerships: Out-licensing completed early-stage drug candidates to established commercial pharmaceutical entities (such as Livzon MabPharm) and collaborating with Contract Development and Manufacturing Organizations (CDMOs) for clinical-grade GMP manufacturing and supply chain scaling.
